Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 5, 2004, Pages 1540-1548

  D'Souza, Warren D ^a,b   Thames, Howard D ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Inhomogeneity; Prostate implant; Radiobiologic parameters; Tumor control probability

Indexed keywords

DOSIMETERS; PARAMETER ESTIMATION; PATIENT TREATMENT; PROBABILITY; TUMORS;

DOSE DISTRIBUTION PATTERNS; TUMOR CONTROL PROBABILITY (TCP);

RADIOTHERAPY;

IODINE 125;

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; HUMAN; IMPLANT; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SIMULATION; STATISTICAL SIGNIFICANCE;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; MALE; MODELS, STATISTICAL; PROSTATIC NEOPLASMS; RADIOBIOLOGY; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS;

EID: 1842424304     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.016     Document Type: Article

References (25)

1. 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
2. Blasko J.C., Grimm P.D., Ragde H. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurie Hypertherm Oncol. 3:1987;131-139.
3. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-249.
4. Grimm P.D., Blasko J.C., Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer Technical concepts in planning, operative technique and evaluation. Atlas Urol Clin North Am. 2:1994;113-125.
5. Willins J., Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;347-353.
6. Bice W.S., Prestidge B.R. A review of postimplant quality assessment in permanent transperineal interstitial prostate brachytherapy. J Brachytherapy Int. 13:1997;297-313.
7. Bice W.S., Prestidge B.R., Grimm P.D., et al. Centralized multi-institutional post-implant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 41:1998;921-927.
8. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
9. 125I implantation for localized prostatic carcinoma. Br J Urol. 72:1993;470-477.
10. Yu Y., Anderson L.L., Li Z., et al. Permanent prostate seed implant brachytherapy Report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys. 26:1999;2054-2076.
11. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 58:1985;515-528.
12. Dale R.G. Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Br J Radiol. 62:1989;241-244.
13. Ling C.C. Permanent implants using Au-198, Pd-103 and I-125 Radiobiological considerations based on the linear-quadratic model. Int J Radiat Oncol Biol Phys. 23:1992;81-87.
14. Dale R.G. Dose-rate effects in targeted radiotherapy. Phys Med Biol. 41:1996;1871-1884.
15. Marchese M.J., Goldhagen P.E., Zaider M., et al. The relative biological effectiveness of photon radiation from encapsulated iodine-125, assessed in cells of human origin I. Normal diploid fibroblasts. Int J Radiat Oncol Biol Phys. 18:1989;1407-1413.
16. Ling C.C., Li W.X., Anderson L.L. The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys. 32:1995;373-378.
17. Waterman F.M., Yue N., Reisinger S., et al. Effect of edema on the post-implant dosimetry of an I-125 prostate implant A case study. Int J Radiat Oncol Biol Phys. 38:1997;335-339.
18. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys. 41:1998;1069-1077.
19. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;1111-1115.
20. 125I seeds. Int J Radiat Oncol Biol Phys. 28:1994;971-978.
21. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
22. Fowler J., Chappell R., Ritter M. Is the α/β for prostate tumors really low? Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
23. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214.
24. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13.
25. Dubray B.M., Thames H.D. The clinical relevance of ratios of radiobiological parameters. Int J Radiat Oncol Biol Phys. 35:1996;1099-1111.